Voss SD - Search Results

1

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.

Weil-Hillman G, Voss SD, Fisch P, Schell K, Hank JA, Sosman JA, Sugamura K, Sondel PM. Weil-Hillman G, et al. Among authors: voss sd. Cancer Res. 1990 May 1;50(9):2683-91. Cancer Res. 1990. PMID: 1691679

2

Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R.

Voss SD, Sondel PM, Robb RJ. Voss SD, et al. J Exp Med. 1992 Aug 1;176(2):531-41. doi: 10.1084/jem.176.2.531. J Exp Med. 1992. PMID: 1500859 Free PMC article.

3

Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression.

Bogner MP, Voss SD, Bechhofer R, Hank JA, Roper M, Poplack D, Hammond D, Sondel PM. Bogner MP, et al. Among authors: voss sd. J Immunother (1991). 1992 Feb;11(2):111-8. J Immunother (1991). 1992. PMID: 1571333

4

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.

Voss SD, Robb RJ, Weil-Hillman G, Hank JA, Sugamura K, Tsudo M, Sondel PM. Voss SD, et al. J Exp Med. 1990 Oct 1;172(4):1101-14. doi: 10.1084/jem.172.4.1101. J Exp Med. 1990. PMID: 1698909 Free PMC article.

5

Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor.

Schiller JH, Witt PL, Storer B, Alberti D, Tombes MB, Arzoomanian R, Brown RR, Proctor RA, Voss SD, Spriggs DR, et al. Schiller JH, et al. Among authors: voss sd. Cancer. 1992 Jan 15;69(2):562-71. doi: 10.1002/1097-0142(19920115)69:2<562::aid-cncr2820690247>3.0.co;2-0. Cancer. 1992. PMID: 1728387 Clinical Trial.

6

Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells.

Fisch P, Malkovsky M, Kovats S, Sturm E, Braakman E, Klein BS, Voss SD, Morrissey LW, DeMars R, Welch WJ, et al. Fisch P, et al. Among authors: voss sd. Science. 1990 Nov 30;250(4985):1269-73. doi: 10.1126/science.1978758. Science. 1990. PMID: 1978758

7

Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly.

Schiller JH, Storer BE, Witt PL, Alberti D, Tombes MB, Arzoomanian R, Proctor RA, McCarthy D, Brown RR, Voss SD, et al. Schiller JH, et al. Among authors: voss sd. Cancer Res. 1991 Mar 15;51(6):1651-8. Cancer Res. 1991. PMID: 1998956 Clinical Trial.

8

The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.

Voss SD, Weil-Hillman G, Hank JA, Sosman JA, Sondel PM. Voss SD, et al. Bull N Y Acad Med. 1989 Jan;65(1):93-110. Bull N Y Acad Med. 1989. PMID: 2690996 Free PMC article. Review. No abstract available.

9

Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM. Voss SD, et al. Cancer Immunol Immunother. 1989;29(4):261-9. doi: 10.1007/BF00199214. Cancer Immunol Immunother. 1989. PMID: 2787694 Free PMC article.

10

Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain.

Voss SD, Leary TP, Sondel PM, Robb RJ. Voss SD, et al. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2428-32. doi: 10.1073/pnas.90.6.2428. Proc Natl Acad Sci U S A. 1993. PMID: 7681595 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Search Page

Filters